A migraine drug that Lundbeck added to its pipeline via its nearly $2 billion acquisition of Alder BioPharmaceuticals won FDA approval on Friday.
The drug, eptinezumab (Vyepti), is part of a new class of antibody therapies developed to prevent migraine attacks... Read more »
The price of insulin, a life-saving treatment discovered a century ago, has been a flashpoint amid the broader drug pricing debate. The FDA is trying to tame high insulin prices by encouraging price competition.
The FDA has historically regarded insulin as... Read more »
Drugs typically go through three phases of clinical testing to support an application for FDA approval. It’s easy to overlook Phase 4, which takes place after a drug reaches the market.
Post-marketing studies aim to identify side effects not observed in... Read more »
Eisai is withdrawing weight-loss drug lorcaserin after a post-marketing study found a higher incidence of cancer in patients who took the medicine.
The FDA said Thursday that its request for removal of the product from the market is voluntary, but Eisai... Read more »
Pfizer and Merck are each cutting ties with a smaller clinical-stage biotech after experimental drugs being developed under separate alliances fell short in human testing.
Pfizer (NYSE: PFE) is walking away from a partnership with GlycoMimetics (NASDAQ: GLYC) a... Read more »
Two experimental drugs from Eli Lilly and Roche have failed a clinical trial testing them as treatments for a form of Alzheimer’s disease caused by certain genetic mutations, the companies reported Monday.
The study, sponsored by Washington University, tested the drugs... Read more »
The president’s State of the Union address was wide-ranging, as they tend to be, but those who tuned in heard mention of two hot health policy topics: price transparency and drug pricing reform.
President Trump asserted that an executive order he... Read more »
An Aimmune Therapeutics drug developed to treat peanut allergy won FDA approval late Friday—the first time the agency has approved an oral immunotherapy for a food allergy.
The Aimmune (NASDAQ: AIMT) drug, Palforzia, was developed to desensitize patients to peanuts... Read more »
If this week is any indication, the steady march of life science companies to Wall Street will continue in 2020. Black Diamond Therapeutics is leading the way, having raised $201 million from its IPO. In its first day of trading, the... Read more »
Some companies that belong to the Biotechnology Industry Organization (BIO), a large industry trade group, convene diverse hiring committees, seek out representation among their suppliers and vendors, and are led by executives that talk regularly about the importance of an inclusive... Read more »
Subtle changes can presage a worsening of a chronic condition, but symptoms may not become apparent to a patient until it’s time to call an ambulance.
BioIntelliSense, a Denver-based digital health startup, has developed a wearable sensor meant to monitor patients’... Read more »
Biopharmaceutical companies focused on advanced therapies are changing industry R&D, manufacturing, and supply chain models according to KPMG.
The audit, tax, and advisory services firm shared details of the trend in its Healthcare & Life Sciences Outlook report, explaining that for... Read more »
So far this year four privately held companies have made the transition to trading on the public markets.
By month’s end, five more are anticipated to join the class of 2020 initial public offerings—and four of those are in life sciences,... Read more »